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Abstract
Background: Streptococcus pneumoniae remains a major cause of childhood morbidity and mortality worldwide.
Nasopharyngeal colonization plays an important role in the development and transmission of pneumococcal
diseases, and infants and young children are considered to be the main reservoir of this pathogen. The aim of this
study was to evaluate the rates and characteristics associated with nasopharyngeal carriage, the distribution of
serotypes and the antimicrobial resistance profiles of Streptococcus pneumoniae among children in a large metropolitan
area in Brazil before the introduction of the 10-valent pneumococcal conjugate vaccine.
Methods: Between March and June 2010, nasopharyngeal swabs were collected from 242 children aged <6 years
attending one day care center and the emergency room of a pediatric hospital. Pneumococcal isolates were identified
by conventional methods and serotypes were determined by a sequential multiplex PCR assay and/or the Quellung
reaction. The antimicrobial susceptibilities of the pneumococci were assessed by the disk diffusion method. MICs for
erythromycin and penicillin were also performed. Erythromycin resistance genes were investigated by PCR.
Results: The overall colonization rate was 49.2% and it was considerably higher among children in the day care center.
Pneumococcal carriage was more common among day care attenders and cohabitants with young siblings. The most
prevalent serotypes were 6B, 19F, 6A, 14, 15C and 23F, which accounted for 61.2% of the isolates. All isolates were
susceptible to clindamycin, levofloxacin, rifampicin and vancomycin. The highest rate of non-susceptibility was
observed for sulphamethoxazole-trimethoprim (51.2%). Penicillin non-susceptible pneumococci (PNSP) accounted for
27.3% of the isolates (MICs of 0.12-4 μg/ml). Penicillin non-susceptibility was strongly associated with serotypes 14 and
23F. Hospital attendance and the presence of respiratory or general symptoms were frequently associated with PNSP
carriage. The two erythromycin-resistant isolates (MICs of 2 and 4 μg/ml) belonged to serotype 6A, presented the M
phenotype and harbored the mef(A/E) gene.
Conclusions: Correlations between serotypes, settings and penicillin non-susceptibility were observed. Serotypes
coverage projected for the 10-valent pneumococcal conjugate vaccine was low (45.5%), but pointed out the potential
reduction of PNSP nasopharyngeal colonization by nearly 20%.
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Background
Streptococcus pneumoniae remains a major cause of
childhood morbidity and mortality worldwide, particu-
larly in lower income countries. Pneumococcal diseases
are the leading source of vaccine preventable deaths,
mostly due to community-acquired pneumonia (CAP)
[1], accounting for approximately 11% of all deaths in
children under 5 years old, excluding neonatal and/or
HIV-positive deaths [2]. This microorganism is also fre-
quently associated with bacteremia and meningitis, and
it is the most common agent of acute otitis media
(AOM) in young children [3].
Brazil was included among the fifteen countries with
the highest estimated number of new cases of pneumo-
nia [4]. Between 2000 and 2008, the mean annual rate of
hospitalization due to CAP was 2,100/100,000 inhabi-
tants: most cases (45%) occurred in children aged less
than 5 years and were caused by S. pneumoniae [5]. The
average incidence of pneumococcal meningitis during
the 2000–2010 period was 1,227 cases/year, with a mean
mortality rate around 30% [6]. In 2010, a survey on the
occurrence of invasive pneumococcal diseases (IPD) in
several Brazilian locations revealed that the majority of
cases corresponded to meningitis (65.1%), followed by
pneumonia (20.5%) and bacteremia (11.2%) [7]. In the
single study available on the etiology of AOM among
Brazilian patients, S. pneumoniae was reported as the
prevalent agent [8], which is consistent with findings of
other geographical regions [3].
More than 90 distinct pneumococcal serotypes have
been described, based on chemical and antigenic varia-
tions of the capsular polysaccharide structure. The capsule
is a major epidemiological marker for tracing pneumococ-
cal infections, and constitutes the base of vaccine formula-
tions currently available against this microorganism. At
the present, two pneumococcal conjugate vaccines, the
10-valent (PCV10) and 13-valent (PCV13) vaccines are
widely available, since the 7-valent (PCV7) is being pro-
gressively removed from the market [9].
PCV7 was introduced in Brazil in 2001, but it was
available to a small portion of the population, since it
was almost restricted to private clinics, and to individ-
uals considered to be at high risk for IPD, who received
vaccination by governmental agencies. Nevertheless, in
March 2010, the PCV10 was included in the Brazilian
Immunization Program, being offered as a free of charge
universal childhood vaccination [5] and it has been,
since then, gradually introduced in different areas of the
country.
Nasopharyngeal colonization was found to play an im-
portant role in the development and transmission of
pneumococcal diseases, and infants and young children
are considered to be the main reservoir of this pathogen
[9]. Thus, surveillance of colonization is important for
vaccination monitoring process and pre-PCV10 era data
are important to predict and assess its impact [10]. The
aim of this study was to determine the prevalence of S.
pneumoniae carriage among children aged less than 6
years attending two institutions in a large metropolitan
area in Brazil, before the introduction of the PCV10.
Methods
Population
From March to June 2010, 242 children under 6 years of
age attending one day care center (DCC; n=102) and the
emergency room of a pediatric hospital (PH; n=140) in
Niterói city were enrolled in the present study. Niterói
city is a large metropolitan area located in the state of
Rio de Janeiro in the Southeastern region of Brazil. The
subjects enrolled in the study did not receive any dose
of the PCV10, since this vaccination was introduced in
this city only in October 2010. Both institutions are pub-
lic and deliver services to low income population. The
age group selected for this study reflects the age range
of the children attending national DCCs.
Study design
A single nasopharyngeal (NP) swab was obtained from
each child, and their accompanying adults answered to
an interviewer-administered questionnaire including
demographic characteristics, symptomatology, if any, at
admission in the study (fever, coryza/sneezing, cough/ex-
pectoration, fatigue/breathlessness, hipoactivity), day
care attendance, chronic or recurrent disease, antibiotic
used in the previous three months, prior hospitalization,
young (aged <6 years) siblings, and if the child had re-
ceived at least one dose of the PCV7.
Isolation and identification of strains
NP specimens were obtained by using a mini tip flocked
with Nylon fiber swab (code 518CS01; Copan, Brescia,
Italy). Swabs were placed in a tube with 1.0 ml of skim
milk tryptone-glucose-glycerin (STGG) transport medium.
All specimens were processed within 6 hours after collec-
tion. NP swabs were streaked onto tryptic soy agar (Difco
Laboratories, Detroit, MI, USA) containing 5% sheep
blood and 5.0 μg/ml gentamicin (Sigma Chemical Co., St.
Louis, MO, USA) and incubated at 36±1°C in 5% CO2-
enriched atmosphere. Suspect colonies were isolated and
identified according to α-hemolysis, susceptibility to
optochin and bile-solubility. If different colony types were
observed in a single culture plate, each colony type was
separately identified.
Determination of capsular serotypes
Serogroups or serotypes of pneumococcal isolates were
deduced by a sequential multiplex PCR assay designed
for Latin America [11,12]. To differentiate among
Neves et al. BMC Infectious Diseases 2013, 13:318 Page 2 of 7
http://www.biomedcentral.com/1471-2334/13/318
Streptococcus pneumoniae serotypes 6A, 6B, and 6C, a
previously described PCR protocol was employed [13].
Isolates not resolved by PCR were serotyped by the
Quellung reaction with antisera kindly provided by the
Centers for Disease Control and Prevention (CDC).
Non-typeable (NT) isolates by both methods were also
tested for specific amplification of the lytA gene [14].
Antimicrobial susceptibility testing
The bacterial isolates were tested by the disk diffusion
method according to the Clinical and Laboratory Stan-
dards Institute recommendations [15]. The antimicrobial
agents tested were: chloramphenicol (30 μg), clindamycin
(2 μg), erythromycin (15 μg), levofloxacin (5 μg), oxacillin
(1 μg), rifampicin (5 μg), sulphamethoxazole-trimethoprim
(23.75 μg / 1.25 μg), tetracycline (30 μg) and vancomycin
(30 μg) (Cecon, São Paulo, SP, Brazil). Isolates with re-
duced susceptibility to penicillin (< 20 mm zone diameter
around the oxacillin disk) and/or erythromycin (< 21 mm
zone diameter) were submitted to determination of
Minimum Inhibitory Concentrations (MIC) by using the
M.I.C.Evaluator™ strips (Oxoid, Basingstoke, Hants, UK).
The presence of macrolide resistance phenotypes was in-
vestigated by the double disk test using erythromycin
(15 μg) and clindamycin (2 μg) disks apart 12 mm from
each other [15].
Detection of erythromycin resistance associated genes
The presence of the erm(A), erm(B) and mef(A/E) genes
was evaluated among erythromycin non-susceptible iso-
lates by PCR as previously described [16].
Ethical considerations
The protocols for collection and informed consent were
approved by the Ethics Committee of the Universidade
Federal Fluminense (CAAE no. 0142.0.258.000-09). Writ-
ten informed consent was obtained from parents or legal
guardians.
Results
Two hundred forty-two subjects aged less than 6 years
attending two public institutions between March and
June 2010 were included in this study. Their median age
was 3 years old (interquartile range: 1.6 – 4.5 years old),
129 of them (53.3%) were male and 113 (46.7%) were
female.
A total of 121 pneumococcal isolates was recovered
from 119 children, revealing an overall colonization rate
of 49.2%. Two phenotypically distinct pneumococcal col-
onies were detected in the respective cultures obtained
from two subjects, indicating co-colonization. The
prevalence of pneumococcal carriage was 42.1% (59/140)
among children at the PH and 58.8% (60/102) among
those at the DCC.
The demographical and clinical characteristics of the
242 children included in this study are shown in Table 1.
The characteristics that showed greater differences be-
tween carriers and non-carriers were day care attend-
ance and cohabiting with siblings under 6 years of age.
Twenty-five serotypes were detected among 117 (96.7%)
of the 121 pneumococcal isolates recovered. The cpsA
pneumococcal identification control gene was not
detected among the four non-typeable (NT) isolates, but
their identification was confirmed by amplification of the
lytA gene. The prevalent serotypes identified were 6B
(15.7%), 19F (12.4%), 6A (9.9%), 14 (9.1%), 15C (8.3%) and
23F (5.8%). Table 2 shows the distribution of serotypes
according to the institution.
Serotype 19F (21.7%; 13/60) was the prevalent type
among carriers from the PH and the presence of respira-
tory symptoms such as coryza/sneezing and cough/ex-
pectoration showed to be associated with colonization
by pneumococci belonging to this serotype. On the other
hand, serotype 6B (23%; 14/61) was the most frequent
among children attending the DCC, mainly in children
aged ≥ 2 years. Regarding simultaneous colonization, in
both the subjects, one of the isolates was NT and the
remaining isolates belonged to serotypes 6B or 19A.
Additionally, the serotypes recovered from the two
pneumococcal carriers who had received only the first
primary immunization dose of the PCV7, both attending
the DCC, were 6B and 15C.
All the isolates were susceptible to clindamycin,
levofloxacin, rifampicin and vancomycin. Susceptibility
to the other five antimicrobial agents tested varied, with
the highest percentage of non-susceptibility being ob-
served for sulphamethoxazole-trimethoprim (51.2%; 62/
121), including 38.8% resistant and 12.4% intermediate
isolates.
Non-susceptibility to penicillin was detected in 27.3%
(33/121) of the isolates and MICs ranged from 0.12 to
4.0 μg/ml. Following the current CLSI criteria for oral
penicillin V, 22 (18.2%) isolates presented intermediate
MICs (Pen-I) and 11 (9.1%) showed MICs indicative of
resistance to penicillin (Pen-R). According to the CLSI
breakpoints for parenteral penicillin (meningitis), all 33
isolates would be considered Pen-R. However, for paren-
teral penicillin (nonmeningitis), only 11 (9.1%) isolates
would be Pen-I and none would be Pen-R (Figure 1).
Penicillin non-susceptible pneumococci (PNSP) were
more common among children attending the PH, being
this characteristic strongly associated with serotypes 14
and 23F (Table 3). Nine (81.8%) of the 11 serotype 14
isolates were PNSP and all of them presented the highest
penicillin MIC observed in this study (4.0 μg/ml). Like-
wise, all seven serotype 23F isolates were non-susceptible
to penicillin, with MICs ranging from 0.18 μg/ml to 0.25
μg/ml. In addition, all the symptoms investigated in this
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study were strongly associated with PNSP carriage, in-
cluding fever, coryza/sneezing, cough/expectoration, fa-
tigue/breathlessness and hipoactivity.
Two isolates were non-susceptible to erythromycin,
showing MICs of 2.0 μg/ml and 4.0 μg/ml. Both isolates
were obtained from children at the PH (each one from a
different child), belonged to serotype 6A, presented the
M phenotype and harbored the mef(A/E) gene. Both iso-
lates were also PNSP, with MICs of 0.25 μg/ml.
Resistance to tetracycline was observed in only two
(1.7%) pneumococcal isolates (one serotype 6B and an-
other NT) that colonized simultaneously the same child
attending the DCC. Eight (6.6%) additional isolates were
intermediate to tetracycline.
Four (3.3%) isolates were resistant to chloramphenicol,
and two of them belonged to serotype 6B. The other two
were NT and represented the only multiresistant isolates
detected in this study, since they were also resistant to
Table 1 Demographic and clinical characteristics of the
242 children enrolled in the present study
Risk factor S. pneumoniae carriage





< 2 years 31 44
≥ 2 years 85 76


















Chronic or recurrent disease
Yes 27 26
No 89 94









Young (< 6 years) siblings
Yes 61 40
No 55 80
Table 1 Demographic and clinical characteristics of the
242 children enrolled in the present study (Continued)
Received at least 1 dose of PCV7
Yes 2 4
No 113 116
aDay care attendance includes all children of the day care center plus those
from hospital whose parents or legal guardians answered “Yes” to question
“Does the child attend a day care center?”; PCV7, 7-valent pneumococcal
conjugate vaccine; Data from seven children were not fully available.
Table 2 Distribution of capsular types among 121
Streptococcus pneumoniae isolates recovered from the
nasopharynx of children living in a large metropolitan
area in Southeastern Brazil
Day care center (n=61) Pediatric hospital (n=60)
Serotypes No. (%) Serotypes No. (%)
6B 14 (23.0) 19F 13 (21.7)
15C 8 (13.1) 6A 8 (13.3)
17F 6 (9.8) 14 7 (11.7)
6A 4 (6.6) 23F 7 (11.7)
11A 4 (6.6) 6B 5 (8.3)
14 4 (6.6) 16F 4 (6.7)
6C 3 (4.9) 10A 2 (3.3)
19A 3 (4.9) 15C 2 (3.3)
23B 3 (4.9) 23A 2 (3.3)
15A 2 (3.3) Othersb 9 (15.0)
19F 2 (3.3) NT 1 (1.7)
Othersa 5 (8.2)
NT 3 (4.9)
aserotypes 3, 18B, 23A, 29 and 34.
bserotypes 4, 9N, 6C, 12F, 18C, 19A, 34, 35B and 39.
NT non-typeable.
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sulphamethoxazole-trimethoprim and non-susceptible to
penicillin (MICs of 0.25 μg/ml).
Among the 140 children attending the PH that were
included in the present study, seven (5.0%) were hospi-
talized with pneumonia, and four of them were also
nasopharyngeal pneumococcal carriers. The isolates re-
covered from these individuals belonged to serotypes
19F (n=3) and 14 (n=1). All of them, except one serotype
19F isolate, were PNSP. However, no microorganisms
were recovered from the blood culture of these patients,
and after treatment using β-lactams the children had
their health restored.
Discussion
The frequency of S. pneumoniae NP carriage was inves-
tigated among children attending two distinct settings in
a large metropolitan area in Brazil. An overall prevalence
of 49.2% was found, and it was considerably higher at
the DCC when compared to the PH (58.8% vs. 42.1%).
The most common characteristics associated with
pneumococcal colonization observed in this study (day
care attendance and cohabitating with young siblings)
were also found in recently published studies carried out
in Taiwan [17] and in the USA [18], reinforcing our find-
ings. Other factors might have accounted for the high
prevalence rate in the present study, such as the low so-
cioeconomic status of the analyzed population and
crowding [19].
Data from the SIREVA II project (2010) revealed that
the most prevalent serotypes associated with IPD among
children less than 5 years old in Latin America were 14,
6B, 19A, 1, 23F, 6A and 19F, accounting for approxi-
mately 60% of these diseases [7]. Although we have not
analyzed invasive isolates, these serotypes, except for
serotype 1 which was not detected, represented 56.2% of
the isolates recovered from the nasopharynx of children
included in this study. Such observations highlight the
importance of pneumococcal carriage, since frequency
of isolation was very similar to the one observed for IPD,
and previous colonization is known to be a step usually
required for the development of invasive infections.
Considering that the currently available conjugate vac-
cines against S. pneumoniae may contribute to eliminate
the asymptomatic carriage, PCV7 and PCV10 would
have an identical theoretical impact (45.5%) in the ana-
lyzed population, since the additional serotypes repre-
sented in the PCV10 (1, 5 and 7F) were not detected.
Regarding PCV13, which contains serotypes 3, 6A and
19A in addition to those provided in PCV10 and is also
approved for use in Brazil, the projected coverage for
pneumococci recovered in the present study was 59.5%.
Nevertheless, in Brazil, this vaccine is currently available
only in private clinics. By setting, this impact would be
considerably lower among children attending the DCC
when compared to those at the PH, as for PCV10 (34.4%
vs. 56.7%) and for PCV13 (47.5% vs. 71.7%).











Pen-I Pen-R Pen-I Pen-R Pen-I Pen-R
Pediatric hospital
Day care center
Figure 1 Distribution of penicillin non-susceptible
(MIC > 0.6 μg/ml) Streptococcus pneumoniae considering the
different MIC breakpoints. Pen, penicillin; R, resistant; I,
intermediate. MIC, Minimum Inhibitory Concentrations. Adopted MIC
breakpoints: oral penicillin V (I = 0.12-1.0 μg/ml; R ≥ 2.0 μg/ml);
penicillin parenteral (nonmeningitis - I = 4.0 μg/ml; R ≥ 8.0 μg/ml);
and penicillin parenteral (meningitis - R ≥ 0.12 μg/ml).
Table 3 Characteristics of penicillin non-susceptible (MIC > 0.6 μg/ml) Streptococcus pneumoniae serotypes recovered
from nasopharyngeal carriers in a large metropolitan area in Southeastern Brazil
Penicillin MIC Number of isolates (%) Serotypes (number of isolates) Institution (number of isolates)
0.12 μg/ml 5 (15.1) 19F (3), 6B, 34 Pediatric hospital
0.18 μg/ml 2 (6.1) 19F, 23F Pediatric hospital
0.375 μg/ml 2 (6.1) 6A, 23F Pediatric hospital
0.25 μg/ml 11(33.3) 23F (5), 6B (3), NT (2), 10A Pediatric hospital (7)
Day care center (4)
0.5 μg/ml 2 (6.1) 6A (2) Pediatric hospital
4.0 μg/ml 11 (33.3) 14 (9), NT (2) Pediatric hospital (5)
Day care center (6)
Total 33 (100)
MIC Minimum Inhibitory Concentrations.
NT non-typeable.
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The reason behind this very low estimated coverage in
the DCC is the prevalence of serotypes 15C, 17F and
11A, ranked from 2nd to 4th position respectively at this
scenario, which are not included in any of the available
conjugate vaccine formulations. These serotypes have
also been found in the nasopharynx of unvaccinated
children aged less than 5 years in a previous Brazilian
study, but they are rarely associated with invasive dis-
eases in Latin America and other regions of the world
[7,20]. Interestingly, serotype 15B/C, together with 6C
and 19A, was one of the serotypes most commonly iso-
lated from children aged <7 years in primary care prac-
tices in Massachusetts, USA, where serotype replacement
post-PCV7 is considered essentially complete [18]. These
serotypes are already circulating among the children in-
cluded in the present study, mostly at the DCC where
they account for almost 25% of the pneumococcal iso-
lates, and this finding can predict serotype replacement
post-PCV10 in our region.
We have also observed association between serotypes,
settings and penicillin non-susceptibility, since serotypes
6B and 19F were strongly associated with children at the
DCC and the PH, respectively, whereas penicillin non-
susceptibility was more common among pneumococci
isolated from children at the PH, being frequently re-
lated to serotypes 14 and 23F.
As previously demonstrated [19], colonization rates
tend to be higher during respiratory tract infections. Al-
though, we have not observed this fact globally in the
present study, serotype 19F carriage was strongly associ-
ated with children who presented respiratory symptoms,
such as coryza/sneezing and cough/expectoration. Also,
it was possible to observe that PNSP colonization was
very frequent among children presenting all the symp-
toms assessed, both general and respiratory.
Despite the strong association of PNSP with serotypes
14 and 23F, non-susceptibility to penicillin was also found
among serotypes 6A, 6B, 10A, and 19F. These results are
in accordance with data in the literature, showing that
most PNSP isolates belong to serotypes 6A, 6B, 9V, 14,
15A, 19F, 19A, and 23F [7,21,22]. Although this associ-
ation is well-documented, non-susceptibility to penicillin
has already been found in other serotypes, such as 3, 6C,
and 18C [7], and in the present study, serotype 10A.
In theory, vaccine coverage projected for isolates re-
covered in the present study could potentially reduce
penicillin non-susceptibility rates from 27.3% to 7.4% or
5% with the use of PCV10 or PCV13, respectively. How-
ever, other authors have described no or low impact on
PNSP carriage post-PCV7 immunization [23,24]. Also,
in a recent study carried out in Korea after optional use
of the PCV7, rates of penicillin non-susceptibility were
found to increase significantly and were strongly associ-
ated with non-vaccine serotypes 6A and 19A [25].
High rates of non-susceptibility to sulphamethoxazole-
trimethoprim have already been described among invasive
and carriage isolates recovered from Brazilian children
and adolescents, corroborating the findings of the present
study [7,26,27].
The low rate of erythromycin resistance observed in
the present study was similar to that obtained for iso-
lates recovered from individuals under 15 years of age
with pneumonia [27], but considerably lower to that
(15.0%) reported in 2010 on the SIREVA II project among
children with invasive infections aged < 5 years [7].
Despite high rates of non-susceptibility to penicillin
and sulphamethoxazole-trimethoprim, the pneumococ-
cal isolates recovered from nasopharynx of the children
analyzed in this study showed a high degree of suscepti-
bility for the majority of the antimicrobial agents tested
and, as previously reported [19,20], this may also reflect
the characteristics of the pneumococcal isolates associ-
ated with diseases in our region.
Conclusions
Our findings indicate a high prevalence of pneumococcal
carriage among the population analyzed and reinforce
previous observations indicating that asymptomatic
colonization by these microorganisms is common among
children, particularly in closed communities and house-
hold contacts. Correlations between serotypes, settings
and penicillin non-susceptibility were observed. Sero-
types coverage projected for the 10-valent pneumococcal
conjugate vaccine was low, but pointed out the potential
reduction of PNSP nasopharyngeal colonization by
nearly 20%.
Since data on isolates from nasopharyngeal colonization
provides relevant information on the potential burden of
pneumococcal diseases, antimicrobial resistance and their
prevention, continued monitoring of prevalent serotypes
and antimicrobial resistance is an important tool to esti-
mate and evaluate the impact of the pneumococcal conju-
gate vaccines. This is essentially important now in Brazil,
where PCV10 has been recently introduced for routine
immunization, since the epidemiology of pneumococcal
diseases varies in response to a selective pressure, which
may probably be in progress already.
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